Wolfe Research analyst Kalpit Patel initiated coverage of Exelixis (EXEL) with a Peer Perform rating and no price target Zanzalintinib is unlikely to fully replenish cabozantinib’s potential lost revenues, the analyst tells investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXEL: